Evidence map›Paper›PMID 38914805›Full record

ArticleBritish journal of cancer2024

Hormone replacement therapy and cancer mortality in women with 17 site-specific cancers: a cohort study using linked medical records.

Chris R Cardwell, Tom A Ranger, Alexander M Labeit, Carol A C Coupland, Blánaid Hicks, Carmel Hughes, Úna McMenamin, Xue W Mei, Peter Murchie, Julia Hippisley-Cox

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chris R CardwellCentre for Public Health, Queen's University Belfast, Belfast, Northern Ireland, UK. c.cardwell@qub.ac.uk.ORCID http://orcid.org/0000-0002-2689-4335
Tom A RangerNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Alexander M LabeitCentre for Public Health, Queen's University Belfast, Belfast, Northern Ireland, UK.
Carol A C CouplandCentre for Academic Primary Care, University of Nottingham, Nottingham, UK.ORCID http://orcid.org/0000-0002-2327-3306
Blánaid HicksCentre for Public Health, Queen's University Belfast, Belfast, Northern Ireland, UK.
Carmel HughesSchool of Pharmacy, Queen's University Belfast, Belfast, Northern Ireland, UK.
Úna McMenaminCentre for Public Health, Queen's University Belfast, Belfast, Northern Ireland, UK.
Xue W MeiNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Peter MurchieDivision of Applied Health Sciences Section, Academic Primary Care, University of Aberdeen, Foresterhill, Aberdeen, UK.ORCID http://orcid.org/0000-0001-9968-5991
Julia Hippisley-CoxNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-2479-7283

Funding

Cancer Research UK (CRUK) C37316/A29656
6 · The paper itself

Abstract

backgroundThere is limited evidence on the safety of Hormone Replacement Therapy (HRT) in women with cancer. Therefore, we systematically examined HRT use and cancer-specific mortality in women with 17 site-specific cancers.

methodsWomen newly diagnosed with 17 site-specific cancers from 1998 to 2019, were identified from general practitioner (GP) records, hospital diagnoses or cancer registries in Scotland, Wales and England. Breast cancer patients were excluded because HRT is contraindicated in breast cancer patients. The primary outcome was time to cancer-specific mortality. Time-dependent Cox regression models were used to calculate adjusted hazard ratios (HR) and 95% confidence intervals (95% CIs) for cancer-specific mortality by systemic HRT use.

resultsThe combined cancer cohorts contained 182,589 women across 17 cancer sites. Overall 7% of patients used systemic HRT after their cancer diagnosis. There was no evidence that HRT users, compared with non-users, had higher cancer-specific mortality at any cancer site. In particular, no increase was observed in common cancers including lung (adjusted HR = 0.98 95% CI 0.90, 1.07), colorectal (adjusted HR = 0.79 95% CI 0.70, 0.90), and melanoma (adjusted HR = 0.77 95% CI 0.58, 1.02).

conclusionsWe observed no evidence of increased cancer-specific mortality in women with a range of cancers (excluding breast) receiving HRT.

Indexed as

Hormone Replacement TherapyNeoplasmsAdultAgedCohort StudiesEnglandFemaleHumansMedical Record LinkageMiddle AgedProportional Hazards ModelsRegistriesScotlandWales

Identifiers

PMID38914805
PMCPMC11333726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.